Samuel C. Bernstein has been elected partner at McGuireWoods, effective January 1, 2019. He represents pharmaceutical and medical device companies regarding FDA approval pathways, fraud and abuse issues, off-label promotion, adverse event reporting, developing and implementing compliance programs, and other regulatory and compliance matters.